No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Zhejiang Hisun Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its portfolio includes both active pharmaceutical ingredients (APIs) and finished drug formulations. The company's extensive therapeutic focus spans oncology, cardiovascular health, infectious diseases, liver support, orthopedics, parasitic infections, and immunosuppression. Additionally, Hisun Pharmaceutical addresses conditions such as weight management, viral infections, tuberculosis, and offers veterinary pharmaceuticals, among other specialized medical applications. Beyond its product lines, the firm provides product consultation and contract manufacturing/research (CMO/CRO) services. Established in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is headquartered in Taizhou, China.
www.hisunpharm.comNo one on the platform currently holds 600267.SS.
No tracked institution reports a position in 600267.SS as of their last filing.
No one on the platform has traded 600267.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.1% | — | — | — | ||
| Rev. Growth % | 7.8% | -1.5% | ||||
| Profit Margin % | 5.1% | 3.7% | 1.7% | |||
| Free Cash Flow Margin % | 15.7% | 13.8% | 6.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.5B | -9.3% | $0.64 | $0.64–$0.64 | — | 1 |
| 2027 | $8.6B | +1.5% | $0.57 | $0.57–$0.57 | — | 1 |
| 2028 | $9.3B | +7.6% | $0.59 | $0.59–$0.59 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.19 | $0.23 | +21.1% |
| 2026-04-16 | $0.18 | $0.30 | +66.7% |
| 2026-04-08 | $-0.03 | $0.07 | +333.3% |
| 2025-09-30 | $0.12 | $0.14 | +16.0% |
| 2025-06-30 | $0.14 | $0.09 | -35.6% |
| 2025-04-16 | $0.09 | $0.17 | +88.9% |
| 2025-03-28 | $-0.03 | $0.08 | +366.7% |
| 2024-10-30 | $0.11 | $0.07 | -36.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. | $11.33 | +0.27% | $13.4B | — |
| 000403.SZPacific Shuanglin Bio-pharmacy Co., Ltd. | $9.92 | -0.80% | $9.4B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.31 | -1.31% | $9.7B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.27 | -0.63% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company |
| $16.15 |
| +0.06% |
| $9.9B |
| — |
| 600216.SSZhejiang Medicine Co., Ltd. | $12.36 | -1.04% | $11.9B | — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.06 | -1.09% | $10.8B | — |
Source: Financial Modeling Prep · peers by sector/industry